CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 1-12 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2027PubMedSupporting evidence

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

2027PubMedSupporting evidence

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026arXivDirectly related

Combining standard chemoradiotherapy with CAR-T cell therapy in malignant gliomas: Insights from an impulsive mathematical framework and virtual trials

Dmitry Sinelshchikov; Nikols Amaru Mora Millán; Miguel Perales-Patón; Juan Belmonte-Beitia; Matteo Italia

Sep 30, 2026

2026CrossrefDirectly related0 citations

CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.

Xudong Wang; Jin Zhang

Jun 1, 2026Journal of Clinical Oncology

2026Semantic ScholarDirectly related0 citations

Integration site analysis in engineered T cell therapies: what we measure, what we miss, and what regulators expect

Deividas Pažėraitis; J. Kupčinskas

Feb 23, 2026Cell and Gene Therapy Insights0 influential

2026PubMedDirectly related

Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.

Chaurasiya S; Kim SI; Sah P; Zhang Z; Vashi Y; Wu H; Cillis J; Park A; Yang A; Woo Y; Xiong G; Liu J; Zhang H; Wang P; Liu C; Fong Y

Jan 1, 2026Frontiers in immunology

2026PubMedSupporting evidence

In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology.

Hu J; Zhu D; Zheng S

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy.

Vitali A; Padlo J; Caramel C; Andersch L; Hartmann LM; Kath J; Grunewald L; Schwiebert S; Winkler A; Talalai E; Biereder T; Wienke J; Molenaar JJ; Launspach M; Delebinski C; Kern A; Astrahantseff K; Wagner DL; Willimsky G; Eggert A; Blankenstein T; Anders K; Künkele A

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Discovery of candidate antibodies and antigens for acute myeloid leukemia therapy by combining whole-cell phage display selection and CRISPR-Cas9 library screening.

Hashimoto K; Konetzki V; Garitano-Trojaola A; Kraus S; Friedel SR; Hudecek M; Peng H; Rader C

Jan 1, 2026Antibody therapeutics

2026PubMedDirectly related

Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.

Fröse J; Chen E; Whittaker CA; Leclerc P; Doherty S; Langenbucher A; Shao J; Hellinger RD; Goulet D; Tammela T; Sánchez-Rivera FJ; Hemann MT

Jan 1, 2026Science advances

2026PubMedDirectly related

Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility.

Schreiber YR; Keller MR; Bower XS; Fuller EC; Woo J; Memmos N; Odde DJ; Leonard JN

Jan 1, 2026bioRxiv : the preprint server for biology

2026PubMedDirectly related

The GPR183-oxysterol axis in cancer: immune trafficking, spatial organization, and therapeutic potential.

Zhuang H; Li F; Li S; Jiang X; Sha W; Pei R; Chen D; Lu Y

Jan 1, 2026Frontiers in immunology